<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942083</url>
  </required_header>
  <id_info>
    <org_study_id>317-12-001</org_study_id>
    <secondary_id>There is no secondary ID.</secondary_id>
    <nct_id>NCT01942083</nct_id>
  </id_info>
  <brief_title>A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open label, non randomized, multicenter study designed to investigate the
      safety and tolerability of escalating doses of OPB-111077 administered orally, once daily in
      subjects with advanced HCC.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision
  </why_stopped>
  <start_date type="Actual">May 29, 2013</start_date>
  <completion_date type="Actual">July 11, 2016</completion_date>
  <primary_completion_date type="Actual">June 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of OPB-111077</measure>
    <time_frame>Within the first cycle [24 days]</time_frame>
    <description>Number of participants with adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the maximum tolerated dose (MTD) of OPB-111077</measure>
    <time_frame>Within the first cycle [24 days]</time_frame>
    <description>• The highest dose that does not lead to discontinuation of dose escalation is defined as the MTD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) properties of OPB-111077 and its metabolites.</measure>
    <time_frame>Within the first cycle [24 days]</time_frame>
    <description>The following PK parameters (Cmax (maximum observed concentration), AUC(area uder the concentration time curve from zero), tmax (Time to maximum plasma concentration), etc.) will be determined using a non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response measured by RECIST(Response Evaluation Criteria in Solid Tumor) 1.1</measure>
    <time_frame>Approximately 3-18 weeks depending on tumor response</time_frame>
    <description>Assessment will be conducted at Screening, end of Cycle 1, end of Cycle 2, end of every 2 cycles thereafter, at the Early Termination (discontinuation) Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of OPB-111077</measure>
    <time_frame>Within the first cycle [24 days]</time_frame>
    <description>Change from baseline on predictable biomarker specified in the protocol</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>OPB-111077</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPB-111077</intervention_name>
    <arm_group_label>OPB-111077</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathologically or clinically diagnosed HCC by Korean Liver Cancer Study Group
             (KLCSG) guidelines.

          2. Subject who has advanced HCC

          3. Documented evidence of unresponsiveness to, intolerance to, or ineligibility for
             sorafenib, or unavailability of appropriate sorafenib treatment

          4. Male or female subject, age at consent ≥20 years and ≤75 years.

          5. Life expectancy ≥12 weeks.

          6. Subjects who agree that they or their partner(s) will practice contraception during
             the study period and 3 months (12 weeks) after the completion of study treatment.

          7. Subjects informed of the diagnosis of advanced HCC who are fully informed about the
             content of the study by the Investigator using the written consent form, and give
             written consent to participate in the study of their own free will.

        Exclusion Criteria:

          1. Past liver transplantation

          2. Uncontrollable hepatic encephalopathy or ascites

          3. Presence of brain metastases

          4. Clinically significant gastrointestinal bleeding in past 6 months or current active
             gastrointestinal bleeding.

          5. Primary malignancy other than HCC

          6. Human immunodeficiency virus (HIV) infection

          7. Severe or poorly controlled complication that may affect the conduct or results of the
             study.

          8. Use of Interferon preparation within 4 weeks (28 days) before start of study treatment
             in the present study.

          9. Pregnant, nursing, or possibly pregnant women, or women desiring to become pregnant
             during the study period

         10. Other cases judged by the Investigator to be ineligible for participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Seoul &amp; Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>May 7, 2017</last_update_submitted>
  <last_update_submitted_qc>May 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

